- For Print
- November 8, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.
Aiming to further expand its contribution to patients in China, Eisai has been working to establish the new Suzhou plant as the plant with the largest production capacity under the Eisai Group on a new industrial site more than five times larger than the former Suzhou plant (oral solid dose production facility scheduled for closure at the end of November 2018) at approximately 134,000m2 in size to further strengthen the stable supply chain as well as improve production efficiency. The new Suzhou plant’s oral solid dose production facility has a production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) which is approximately double that of the former Suzhou plant, and handles the formulation and packaging of oral solid dose products such as Methycobal®, Aricept® and Pariet® for the domestic Chinese market. In addition, ECI established a parenteral facility (production capacity: 60 million bottles per year) in advance in November 2014, where it manufactures the injection formulation of Methycobal.
Eisai’s business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. With the full-scale commencement of operations at the new Suzhou plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.
Public Relations Department,
Eisai Co., Ltd.
[Notes to editors]
1. Outline of New Suzhou Plant
Location: 168 Xingpu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China
Site area: Approximately 134,000 m2
(1) Oral Solid Dose Production Facility
- Floor space: Approximately 20,240 m2 / Three floors
- Main functions: Formulation, packaging, storage, etc.
- Products to be manufactured: Methycobal, Aricept, Pariet and other products
(2) Parenteral Production Facility
- Floor space: Approximately 5,690 m2 / Two floors
- Products manufactured: Methycobal injection and other products
(3) Administration Building
- Floor space: Approximately 2,230 m2 / Two floors
- Main facilities: Offices, meeting rooms, cafeteria, etc.
(4) Distribution Warehouse
- Floor space: Approximately 7,812 m2 / One floor